Under 10% of patients that would benefit from obesity jabs such as Wegovy have access to them, caution the global health agency as it releases its inaugural recommendations on the medications.
Given more than one billion people worldwide currently living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant obstacles to broad access to the injections that can aid individuals in losing significant body mass, says the organization.
Skinny Jab Supply Crisis
Even in the present most favorable scenario, the manufacturing of GLP-1 therapies could only cover around 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to increase access, through strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Jabs Work
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so users eat less.
Individuals commonly see weight reduction after several weeks of beginning the regular doses.
Research points to users may see weight return within a year of stopping the medication, as their usual hunger return.
To be above a healthy weight raises your risk for experiencing health problems, including diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts individuals in every country and was responsible for millions of deaths worldwide in 2024, as per the health agency.
